A Mechanistic Hypothesis for the Cytochrome P450-Catalyzed Cis-Trans Isomerization of 4-Hydroxytamoxifen: An Unusual Redox Reaction

We provide a detailed description of the cis-trans isomerization of 4-hydroxytamoxifen/endoxifen catalyzed by several isoforms from the cytochrome P450 (CYP) superfamily, including CYP1B1, CYP2B6, and CYP2C19. We show that the reactions mainly involve redox processes catalyzed by CYP. DFT calculation results strongly suggest that the isomerization occurs via a cationic intermediate. The cationic cis-isomer is more than 3 kcal/mol more stable than the trans form, resulting in an easier conversion from trans-to-cis than cis-to-trans. The cis-trans isomerization is a rarely reported CYP reaction and is ascribed to the lack of a second abstractable proton on the ethenyl group of the triarylvinyl class of substrates. The cationic intermediates thus formed instead of the stable dehydrogenation products allow for isomerization to occur. As a comparison, the reactions for the tamoxifen derivatives are compared to those of other substrates, 4-hydroxyacetanilide and raloxifene, for which the stable dehydrogenation products are formed.

[1]  J. Groves,et al.  Aliphatic hydroxylation via oxygen rebound. Oxygen transfer catalyzed by iron , 1976 .

[2]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[3]  Yong Wang,et al.  P450 enzymes: their structure, reactivity, and selectivity-modeled by QM/MM calculations. , 2010, Chemical reviews.

[4]  R. Friesner,et al.  Insights into the different dioxygen activation pathways of methane and toluene monooxygenase hydroxylases. , 2011, Journal of the American Chemical Society.

[5]  Victor Guallar,et al.  Peripheral heme substituents control the hydrogen-atom abstraction chemistry in cytochromes P450 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. Kuramochi.  Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. , 1996, Journal of medicinal chemistry.

[7]  Silvio E. Biali,et al.  Threshold Rotational Mechanisms and Enantiomerization Barriers of Polyarylvinyl Propellers , 1997 .

[8]  S. Nelson,et al.  Lack of evidence for N-hydroxyacetaminophen as a reactive metabolite of acetaminophen in vitro. , 1980, Biochemical pharmacology.

[9]  Takashi Kamachi,et al.  A theoretical study on the mechanism of camphor hydroxylation by compound I of cytochrome p450. , 2003, Journal of the American Chemical Society.

[10]  Minoti Sharma,et al.  Biotransformation of tamoxifen in a human endometrial explant culture model. , 2003, Chemico-biological interactions.

[11]  M. Jarman,et al.  A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. , 1994, Carcinogenesis.

[12]  H. Rochefort,et al.  Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. , 1982, Cancer research.

[13]  M. Newcomb,et al.  Hypersensitive Mechanistic Probe Studies of Cytochrome P450-Catalyzed Hydroxylation Reactions. Implications for the Cationic Pathway , 1998 .

[14]  Dongxiao Sun,et al.  Potential Role of UGT Pharmacogenetics in Cancer Treatment and Prevention , 2009, Annals of the New York Academy of Sciences.

[15]  Sason Shaik,et al.  What factors affect the regioselectivity of oxidation by cytochrome p450? A DFT study of allylic hydroxylation and double bond epoxidation in a model reaction. , 2002, Journal of the American Chemical Society.

[16]  Roderick E Hubbard,et al.  Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  L. Sternson,et al.  Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer. , 1981, Biopharmaceutics & drug disposition.

[18]  C. Cramer,et al.  Universal solvation model based on solute electron density and on a continuum model of the solvent defined by the bulk dielectric constant and atomic surface tensions. , 2009, The journal of physical chemistry. B.

[19]  J. Thompson,et al.  Cytochrome P-450-catalyzed rearrangement of a peroxyquinol derived from butylated hydroxytoluene. Involvement of radical and cationic intermediates. , 1986, The Journal of biological chemistry.

[20]  R. Martin,et al.  Oxidation of substituted N,N-dimethylanilines by cytochrome P-450: estimation of the effective oxidation-reduction potential of cytochrome P-450. , 1989, Biochemistry.

[21]  V. Jordan,et al.  Tamoxifen: a most unlikely pioneering medicine , 2003, Nature Reviews Drug Discovery.

[22]  J. Dawson,et al.  Heme-Containing Oxygenases. , 1996, Chemical reviews.

[23]  C. Osborne,et al.  Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. , 1991, Journal of the National Cancer Institute.

[24]  B. Katzenellenbogen,et al.  Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. , 1984, Cancer research.

[25]  T. Cheatham,et al.  Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity. , 2010, Biochemistry.

[26]  Chang-Guo Zhan,et al.  Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. , 2011, Journal of the American Chemical Society.

[27]  C. Reilly,et al.  CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene. , 2010, Biochemistry.

[28]  V. Jordan,et al.  Ligand interaction at the estrogen receptor to program antiestrogen action: a study with nonsteroidal compounds in vitro. , 1988, Endocrinology.

[29]  G. Tucker,et al.  Interindividual variation in the isomerization of 4-hydroxytamoxifen by human liver microsomes: involvement of cytochromes P450. , 1994, Carcinogenesis.

[30]  C. Courseille,et al.  [p-(Diméthylamino-2 éthoxy)phényl]-1 trans-diphényl-1,2 butène-1 (tamoxfène) (ICI-46474) , 1979 .

[31]  Ruth Nussinov,et al.  How Does the Reductase Help To Regulate the Catalytic Cycle of Cytochrome P450 3A4 Using the Conserved Water Channel? , 2010, The journal of physical chemistry. B.

[32]  David A. Flockhart,et al.  Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[33]  Z. Rappoport,et al.  Stable simple enols. III: Static and dynamic NMR behavior of crowded triarylethenols and related compounds. Three-ring flip as the threshold mechanism for enantiomerization of crowded triarylvinyl propellers , 1984 .

[34]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[35]  Sason Shaik,et al.  Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes. , 2005, Chemical reviews.

[36]  E. Gillam,et al.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[37]  W. McGuire,et al.  Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Newcomb,et al.  A nonsynchronous concerted mechanism for cytochrome P-450 catalyzed hydroxylation , 1995 .

[39]  Donald G. Truhlar,et al.  Density Functionals with Broad Applicability in Chemistry , 2008 .

[40]  J. Gustafsson,et al.  Structural Insights into Corepressor Recognition by Antagonist-bound Estrogen Receptors* , 2007, Journal of Biological Chemistry.

[41]  F. Guengerich,et al.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.

[42]  J. Groves.  Key elements of the chemistry of cytochrome P-450: The oxygen rebound mechanism , 1985 .

[43]  D. Truhlar,et al.  The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: two new functionals and systematic testing of four M06-class functionals and 12 other functionals , 2008 .

[44]  S. Shaik,et al.  A proton-shuttle mechanism mediated by the porphyrin in benzene hydroxylation by cytochrome p450 enzymes. , 2003, Journal of the American Chemical Society.

[45]  Sason Shaik,et al.  Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes. , 2004, Chemical reviews.

[46]  Hui Chen,et al.  The directive of the protein: how does cytochrome P450 select the mechanism of dopamine formation? , 2011, Journal of the American Chemical Society.

[47]  F. Guengerich,et al.  Chemical mechanisms of catalysis by cytochromes P-450: a unified view , 1984 .

[48]  G. Leclercq,et al.  Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy] phenyl]-5H-benzocycloheptene, a nonisomerizable analogue of tamoxifen. X-ray crystallographic studies. , 1986, Journal of medicinal chemistry.

[49]  S. Shaik,et al.  Oxygen economy of cytochrome P450: what is the origin of the mixed functionality as a dehydrogenase-oxidase enzyme compared with its normal function? , 2004, Journal of the American Chemical Society.

[50]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.